COMPLIANCE OF RECOMMENDATIONS FOR THE PREVENTION OF HEPATITIS B VIRUS REACTIVATION DURING DARATUMUMAB TREATMENT

Miralles Andreu, G; Pomares Bernabeu, M; Gutierrez Palomo, S; Jiménez Pulido, IP; Soriano Irigaray, L; Navarro Ruiz A.
Hospital General Universitario de Elche, Pharmacy Department, Elche, Spain.

BACKGROUND AND IMPORTANCE

• June 2019 → Risk of reactivation due to hepatitis B virus (HBV) in patients treated with daratumumab.
• Recommendation: HBV screening in patients before daratumumab initiation and in ones already under treatment.
• Risk factors:
  ✓ Previous autologous stem cell (ASCT)
  ✓ Concurrent and/or prior immunosuppressive therapy (IT)
  ✓ Prevalence HBV regions

AIM AND OBJECTIVES

To analyse the level of compliance with the recommendations for the prevention of HBV reactivation and the risk in our hospital.

MATERIALS AND METHODS

• Descriptive retrospective observational study
• Patients treated with daratumumab since it was commercialized (January 2017 – September 2020)

<table>
<thead>
<tr>
<th>Variables collected</th>
<th>Information was collected from Abucasis®, Farmis® y Gestlab®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Age</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Daratumumab start date</td>
</tr>
<tr>
<td>VHB reactivation risk factors</td>
<td>Serology tests</td>
</tr>
<tr>
<td>HBV vaccination</td>
<td>HB infection</td>
</tr>
</tbody>
</table>

RESULTS

➢ 20 patients included
➢ Median 70±17 years old
➢ 60% male

Main diagnosis:
➢ 95% multiple myeloma
➢ 5% amyloidosis

Risk factors for HBV reactivation:
➢ 20% received previous ASCT
➢ 90% treated with IT

Jan 2017  Daratumumab already initiated  Patients: 45%  Daratumumab new treatments  Sep 2020  Patients: 55%

- 44% had an HBV serology test before daratumumab
- 44% HBV vaccinated
- Serology tests (HBs-Ag and Anti-HBc) were negative

HBV reactivations were not detected

➢ 55% had an HBV serology test before daratumumab
➢ 9% HBV vaccinated
➢ 1 patient was positive for HBs-Ag and Anti-HBc
  o Complementary tests resulted in a past HBV infection
  o Recommendation:
    • Prophylaxis with tenofovir starting 15 days before
    • Trimestral serology tests

CONCLUSION

➢ Only 65% of the patients have at least one HBV serology test.
➢ More serology tests should be carried out to detect risk patients.
➢ No HBV reactivations were detected at our hospital.

farmacia_elx@gva.es  5PSQ-156  L01-Cytostatics